Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Samb2344 May. 14 at 10:13 PM

$ABCL I added just for us to dip off.. love it

0 · Reply

Ed_Ng May. 14 at 9:43 PM

$ABCL so happy now. Thanks everyone!

1 · Reply

tradersunion353 May. 14 at 9:43 PM

$ABCL who are these clowns still pumping this overhyped underperforming junk

0 · Reply

snowPOW May. 14 at 8:55 PM

$ABCL interesting noise today.

0 · Reply

VoxChameleon May. 14 at 8:55 PM

$ABCL you are all smart enough that this will be over $5 by next week. It’s fun to talk smack but let’s be real. Average is $4.53. 11k shares. I’ll make $5K and call It a day. Go Canada.

1 · Reply

nUme22 May. 14 at 8:39 PM

$ABCL always the truth.. Canadian scams. almost as bad as Israeli scams

1 · Reply

PorkchopSquats May. 14 at 8:36 PM

$ABCL @DeMampCamp Still bullish long term, but you’re still an idiot short term.

1 · Reply

tradersunion353 May. 14 at 8:21 PM

$ABCL clowns how is that pumpiny adding and loading work i told you not to fall for that demamp clown zero hopes that this willl rise on phase 2 data

1 · Reply

Plan2TradeTrade2Plan May. 14 at 8:02 PM

$ABCL the news is out. Nowhere to go but down I guess. Can’t find support.

1 · Reply

VoxChameleon May. 14 at 7:59 PM

$ABCL Canada. Lmfao.

0 · Reply

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 2 days ago

AbCellera price target raised to $8 from $7 at Stifel

2026-05-11T21:58:40.000Z - 2 days ago

AbCellera Biologics options imply 9.7% move in share price post-earnings

May 11, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 days ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 7 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 9 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 21, 2026, 1:30 PM EDT - 23 days ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 24 days ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 5 weeks ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 6 weeks ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 2 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

2026-02-24T21:15:21.000Z - 2 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 4 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T14:36:23.000Z - 4 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 4 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 5 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

2025-11-07T11:16:20.000Z - 6 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

Nov 6, 2025, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

2025-09-10T13:20:54.000Z - 8 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 8 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

2025-08-08T13:26:29.000Z - 9 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

2025-06-11T13:45:23.000Z - 1 year ago

Unusually active option classes on open June 11th

AFRM BILI FXE LAES PCG QUBT RGTI

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

2025-05-30T17:05:30.000Z - 1 year ago

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Samb2344 May. 14 at 10:13 PM

$ABCL I added just for us to dip off.. love it

0 · Reply

Ed_Ng May. 14 at 9:43 PM

$ABCL so happy now. Thanks everyone!

1 · Reply

tradersunion353 May. 14 at 9:43 PM

$ABCL who are these clowns still pumping this overhyped underperforming junk

0 · Reply

snowPOW May. 14 at 8:55 PM

$ABCL interesting noise today.

0 · Reply

VoxChameleon May. 14 at 8:55 PM

$ABCL you are all smart enough that this will be over $5 by next week. It’s fun to talk smack but let’s be real. Average is $4.53. 11k shares. I’ll make $5K and call It a day. Go Canada.

1 · Reply

nUme22 May. 14 at 8:39 PM

$ABCL always the truth.. Canadian scams. almost as bad as Israeli scams

1 · Reply

PorkchopSquats May. 14 at 8:36 PM

$ABCL @DeMampCamp Still bullish long term, but you’re still an idiot short term.

1 · Reply

tradersunion353 May. 14 at 8:21 PM

$ABCL clowns how is that pumpiny adding and loading work i told you not to fall for that demamp clown zero hopes that this willl rise on phase 2 data

1 · Reply

Plan2TradeTrade2Plan May. 14 at 8:02 PM

$ABCL the news is out. Nowhere to go but down I guess. Can’t find support.

1 · Reply

VoxChameleon May. 14 at 7:59 PM

$ABCL Canada. Lmfao.

0 · Reply

sogenerous May. 14 at 7:58 PM

$ABCL I mean what did you expect ?

0 · Reply

VoxChameleon May. 14 at 7:54 PM

$ABCL lmfao!!!! What a pos.

0 · Reply

VoxChameleon May. 14 at 7:45 PM

$ABCL close a 1.5 billion dollar Canadian company low of day -7% on no news. 20-% in 3 days. So fitting for that weak ass country.

0 · Reply

VoxChameleon May. 14 at 7:32 PM

$ABCL freaken Canadians man. Oh golly gee they shorted us 20% + in 3 days but we say nothing. Weak ass country man.

1 · Reply

VoxChameleon May. 14 at 7:26 PM

$ABCL a stock like this 1.5 billion cap shouldn’t go down 7% on no news. Brutal.

1 · Reply

VoxChameleon May. 14 at 7:22 PM

$ABCL bought too many shares at average $4.58. Oh well. It will definitely surpass that and be $5+ soon once these savages relax.

1 · Reply

VoxChameleon May. 14 at 7:18 PM

$ABCL lowest volume in probally a month and they are able to short it this low. Impressive.

0 · Reply

DeMampCamp May. 14 at 7:04 PM

$ABCL One of those days you feel like screaming with frustration! The day traders on Twitter win once again, sell off and take their profits and then they'll be rewarded with another low entry. Time to shut my brokerage app down for the day and spend my energy on something else

2 · Reply

VoxChameleon May. 14 at 6:54 PM

$ABCL freaken brutal. Canadian shitshow.

1 · Reply

tradersunion353 May. 14 at 6:37 PM

$ABCL Punch in the face of fake longs and pumpers here.. And that clown Demamp... 🖕he/she comes with narratives when ever this POS drops

0 · Reply

Ed_Ng May. 14 at 6:21 PM

$ABCL this goes big now. Hope you listened ;-). This scam always act like that after earnings

0 · Reply

hichemben May. 14 at 5:26 PM

$ABCL Entire biotech sector is down today, I guess due to the FDA commissioner news earlier this week. So it's nothing to do with ABCL! Major focus on memory and quantum stocks past days, hopefully sector rotation next week until then, nothing things to the fundamentals and P1 results is only a start🚀💎

1 · Reply

Market Cap	1.51B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	7,258,974
Avg Vol	5,141,984
Day's Range	N/A - N/A
Shares Out	305.27M
Stochastic %K	46%
Beta	1.02
Analysts	Strong Sell
Price Target	$9.43